Background HIV patients are at increased cardiovascular risk while available European cardiovascular recommendations are ambiguous. Methods Retrospective analysis of 389 HIV-patients was conducted. Cardiovascular risk was determined by D:A:D, Framingham and SCORE scales. Patients were divided into risk groups as recommended by EACS 2019, PTN AIDS 2019 and ESC/EAS 2019 Guidelines and hypolipemic treatment was evaluated. Results In total, 389 HIV-positive patients took part in the study, most of whom were men (n = 312, 80.4%), mean age 41.69±10years. Mean lipid levels among all HIV patients: Tch:177.2±36mg/dl, HDL:48.9±18mg/dl, LDL:103.8±31mg/dl, TG:143.3±81mg/dl, AIP:0.45±0.3, non-HDL:129.2±36 mg/dl. Most of the participants (n = 360, 92.5%) were assigned to the high cardiovascular risk group according to ESC/EAS and PTN AIDS guidelines. The achievement of therapeutic LDLs according to ESC/EAS was 10.3% for those at very high cardiovascular risk (8.7% on lipid lowering treatment vs. 16.7% without hypolipemic drugs) and 12.0% (5.8% treated vs. 13.6% untreated) at high cardiovascular risk; according to PTN AIDS,17.2% achievement was noted by the very high-risk group (13% treated vs. 33.3% untreated), and 45.9% for the high-risk group (37.7% treated vs. 48.0% untreated); according to EACS Guidelines, 2.5% achievement in secondary prevention (3.8% treatedvs. 0% untreated) and 24.7% in primary prevention (22.2% treated vs. 26.1% untreated). Mean doses of statins were 8.75mg±6mg (Rosuvastatin) and 22.35±19mg (Atorvastatin). Conclusions The achievement of therapeutic LDLs by all recommendations is unsatisfactory, and generally worse in patients on lipid lowering therapy. Hypolipemic treatment of our HIV patients is based on low doses of statins, even in secondary prevention.

No abstract

Background/Introduction Recently, HIV patients' life expectancy has been significantly improved due to HAART. It is estimated that HIV positive individuals experience twice the risk of cardiovascular diseases rather than a general population and suffer from cardiovascular incidents in mean age 46 years. However there is no consensus between cardiovascular recommendations for this group of patients. Purpose The aim of the study is the analysis of HIV patients in the light of different cardiovascular recommendations and thus highlighting the inaccuracies of guidelines for this specific group of patients. Methods We performed retrospective analysis of 388 HIV infected patients based on medical records. Then we confronted our patients with different cardiovascular recommendations (PTN AIDS and ESC/EAS 2019 Dyslipidemia Guidelines vs. EACS Guidelines 2019). Results HIV-positive patients included in the study were: 311 men (80.4%) and 77 women (19.6%) in average age 41.7±10 years. The average BMI was 25.3±5 kg. Average HIV infection time was 8.96±7 years. Mean antiretroviral (arv) treatment duration was 4.6±3 years. Eleven participants (2.8%) had ischemic heart disease, 23.5% had hypertension and 3.4% HIV patients were diabetics. Half of patients (50.3%) were active smokers. Fourteen HIV patients (3.6%) experienced cardiovascular incidents in mean age 41.8±6 years. The actual average LDL in those patients is 93.14±21 mg/dl and currently only one of them achieves therapeutic LDL. HIV patients in consideration of PTN AIDS and ESC/EAS 2019 Dyslipidemia Guidelines vs. EACS Guidelines 2019 were scheduled in the Table. Conclusion(s) HIV patients included in our study poorly reach therapeutic recommendations neither provided by ESC/EAS and PTN AIDS or EACS Guidelines. Therapeutic goals reachability is worse in patients on lipid lowering therapy which along with low mean doses of statins indicates that HIV patients hypolipemic treatment is insufficient. There is no consensus on European cardiovascular guidelines for HIV patients, and thus there is a huge gap between recommendations and clinical practice. Funding Acknowledgement Type of funding source: None